Aratana Therapeutics Inc. (PETX) Jumps 8.39% on January 14

Equities Staff |

Aratana Therapeutics Inc. (PETX) was among the biggest gainers on the Russell 2000 for Thursday January 14 as the stock popped 8.39% to $3.23, representing a gain of $0.25 per share. Some 829,850 shares traded hands on 3,972 trades, compared with an average daily volume of 550,417 shares out of a total float of 35.01 million. The stock opened at $3.01 and traded with an intraday range of $3.31 to $2.91.

After today's gains, Aratana Therapeutics Inc. reached a market cap of $113.07 million. Aratana Therapeutics Inc. has had a trading range between $20.63 and $2.96 over the last year, and it had a 50-day SMA of $5.85 and a 200-day SMA of $12.32.

Aratana Therapeutics Inc is a development-stage biopharmaceutical company. It is engaged in licensing, development and commercialization of prescription medicines for companion animals.

Aratana Therapeutics Inc. is based out of Kansas City, KS and has some 60 employees. Its CEO is Steven Peter.

For a complete fundamental analysis analysis of Aratana Therapeutics Inc., check out’s Stock Valuation Analysis report for PETX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…